CTI and the Alliance for Lupus Research: Rewiring the R&D Ecosystem

Dr. Anthony J. Coyle, Centers for Therapeutic Innovation
Kenneth M. Farber, Alliance for Lupus Research
Collaboration: Pfizer’s Centers for Therapeutic Innovation and the Alliance for Lupus Research

- ALR and CTI are co-funding novel translational research projects driven by leading academic medical centers
- Structured pathway for translating scientific ideas into a clinical program
- Partnership announced November 2012
- First-of-its-kind collaboration in lupus
Pfizer’s CTI: Leveraging External Innovation and Internal Expertise

**Identifying Innovative & Differentiated Science**
- 4 CTI locations
- 23 Academic institutions
- ~500 Proposals received
- 25 Funded projects and teams

**Internal Collaboration**
- Working with Pfizer’s Partner Lines
- Aligned with Pfizer’s Research and Business Units
- Dedicated Clinical and Regulatory resources

**Delivering Quality for Sustainable Innovation**
- Opportunity for rapid clinical execution
- New, differentiated therapeutics

CTI integrates external innovation and internal drug discovery expertise to rapidly translate breaking science into clinical studies
CTI’s Academic Network

70 External Academic Reviewers, 23 Leading Academic Medical Centers, 12 CTSA Institutions, 8 National Academy of Science Members

CTI - Boston

CTI - New York

CTI - California
Landscape is evolving from a disparate group of individual players... To a holistic ecosystem fueled by collaboration.
CTI’s Partnership Strategy

- Joint scientific decision making
- Leveraged AMC and pharma resources to speed drug discovery

- 3:3 Joint selection committee
- Collaborate on proposal review, monitor selected programs

Grant award based on Statement of Work budget
About the Alliance for Lupus Research

- Mission: to find better treatments and ultimately prevent and cure lupus by funding biomedical research
- National voluntary health organization based in New York City
- Founded in 1999 by Robert Wood Johnson, IV
- ALR Board of Directors supports 100% of fundraising and administrative costs

About Lupus
- Debilitating autoimmune disease
- Affects an estimated 1.5 million Americans
- 90% of those affected are women
- Only one drug has been approved for treating lupus in the past 52 years
Alliance for Lupus Research Strengths

• Funding best lupus research we can find globally since 1999
• More than $91 million invested in lupus research to date
• Support extensive network of investigators’ work
• About 1/3 of the drugs in development today for lupus have some history in early stage research funded by the ALR
• Able to move quickly on decisions working with corporate partners
• Open to innovative partnership models that speed drug discovery and translation from lab to patients
Partnership Benefits

For CTI

• Co-funding
• Networks of investigators
• Access to data, including samples, study results
• Access to patients

For ALR

• Co-funding
• Access to Pfizer’s resources, including labs, scientists
• Opportunity to leverage foundation’s resources for potential therapeutic or cure
Partnership Strategy

• Joint decision making – equal representation on proposal selection and evaluation committee

• Milestone-driven – funding is tied to clear go/no-go milestones, rather than a pre-defined length of time for projects

• Focus on results – project goals determined during SOW process and evaluated regularly; projects face termination if they do not meet pre-determined goals

• Funding follows success – where evidence suggests high-potential projects, additional financial support can be very significant
Accomplishments

Four projects, three partners:

• Hospital for Special Surgery
• Mt. Sinai Medical Center
• Massachusetts General Hospital
Questions?